Cogent Biosciences Cash Flow Statement
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.00+0.92 (+3.06%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences free cash flow
In fiscal 2025, Cogent Biosciences generated -$264.4 million of operating cash flow and spent $1.6 million on capital expenditures. That left free cash flow of -$266.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -328.94M | -255.86M | -192.41M | -140.24M | -72.27M | -74.81M | -31.83M | -34.53M | -25.49M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.60M | 2.50M | 2.30M | 800.00K | 147.00K | 720.00K | 1.29M | 1.32M | 1.17M |
| Stock-Based Compensation | 46.08M | 39.74M | 30.62M | 18.37M | 11.69M | 6.02M | 3.24M | 3.09M | 1.34M |
| Change in Working Capital | -915.00K | 1.36M | 4.69M | 1.34M | -976.00K | -1.34M | -15.73M | -4.73M | -4.04M |
| Operating Cash Flow | -264.44M | -207.79M | -153.62M | -118.64M | -58.76M | -35.85M | -41.51M | -32.49M | -25.84M |
| Capital Expenditures | -1.55M | -573.00K | -2.80M | -6.86M | -1.72M | — | -33.00K | -549.00K | -912.00K |
| Investing Cash Flow | -399.53M | 38.28M | -97.82M | -124.72M | -1.72M | 8.42M | 23.16M | -10.53M | 13.59M |
| Debt Issued | 49.29M | 0 | 0 | — | — | — | — | — | — |
| Debt Repaid | -54.63M | 0 | 0 | — | — | — | — | — | — |
| Financing Cash Flow | 878.23M | 214.45M | 163.54M | 163.56M | 37.98M | 232.20M | 108.00K | 70.35M | -729.00K |
| Net Change in Cash | 214.26M | 44.94M | -87.91M | -79.80M | -22.51M | 204.77M | -18.25M | 27.33M | -12.98M |
| Free Cash Flow | -266.00M | -208.36M | -156.42M | -125.50M | -60.48M | -35.85M | -41.55M | -33.04M | -26.75M |
This table shows 9 annual periods of Cogent Biosciences's cash flow statement, from FY 2025 back to FY 2017, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a cash flow statement?